x
ServiziMenu principaleHome

Curriculum

 

Seminar 1 

Module 1 

Module 2

Seminar 2

Module 3

Module 4

Seminar 3

Total 

Timeline

 2018
11-14 April

2018
mid Apr/ mid Jul

2018
mid Jul/ mid Oct

2018
19-23 Oct

2018-19
Nov/mid Jan
2019

2019
Mid Jan/Mar


2019
April

12 months 

Content

Reading materials
+
CAS LC course
+
ELCC

 

Epidemiology,
prevention,
biology and
pathology of lung
cancer and
other thoracic malignancies

 Principles of
lung cancer research



Reading materials
+
CAS LC course
+
Selected sessions
of the ESMO Congress

Principles of
NSCLC diagnosis
and treatment

Principles of
treatment
of SCLC, MPM,
thymoma &
thymic cancer

Pre-seminar
preparation of
a clinical case presentation
+
CAS LC course
including
final exam

 

Workload

25 hrs
in-person
+ 5 hrs reading
materials

26 units
78 hrs
Distance learning
+ test

24 units
72 hrs
Distance learning
+ test

25 hrs in-person
+ 5 hrs reading materials

30 units
90 hrs
Distance learning
+ test

30 units
90 hrs
Distance learning
+ test

25 hrs
in-person
+ 5 hrs
preparation
of a clinical
case
incl. certificate exam

90 hrs
seminars +
330 hrs
distance l.
420 hrs

Credits

1 ECTS 

5 ECTS

1 ECTS 

3 ECTS

3 ECTS

1 ECTS

14ECTS 


CAS LC:
separate and specific seminar for Certificate of Advanced Studies in Lung Cancer participants

ELCC: Join the European Lung Cancer Conference, Geneva - ESMO: Join the European Society for Medical Oncology Congress (selected sessions)

The extensiveness of the Module’s programme is expressed in Units.
1 Unit equals to 3 hours of workload, consisting of a 30-minute lecture and 2,5 hours of additional reading.
For instance: 2 Units = 6 hours of workload = 60-minute lecture + 5 hours of additional reading.
The Modules end with a multiple-choice test.

The extensiveness of the Seminar’s programme is 30 hours, with approximately 25 hours of attendance and 5 hours of additional reading or of the preparation of a clinical case presentation.
The Seminars are assessed within the final multiple-choice exam.

 

 Seminar 1

 CAS Lung Cancer programme +
 Participation in the European Lung Cancer Conference (ELCC)

 

 Date and
 place
 10-14 April 2018, Geneva, Switzerland

 

 ECTS
 1  
 Assessment  Included in final exam  
 Workload
 hours   
 

30

 

Pre-reading

Wednesday, 11 April 2018

8:30
Introduction and programme overview
[Programme Chairs: Matthias Guckenberger, UZH, CH and Rolf Stahel, UZH, CH]

9:00
Introduction to the e-learning platform
Martin Butz, Soon Systems, DE

9:30
Communication with the lung cancer patient workshop, part I
[Alexander Kiss, University of Basel, CH]

10:30
Coffee break

10:45
Communication with the lung cancer patient workshop, part II

12:45
Buffet lunch

To complete the workload required by the CAS Lung Cancer programme, participants will attend the ELCC 2018 conference according to the following programme.

When parallel sessions are offered, participants may choose the topic of highest interest.

13:45-14:15
Keynote lecture - HHH Award Lecture

14:30-16:00
Parallel sessions: First line for oncogene addicted lung cancer / Combined treatment stage III

16:30-18:00
Parallel sessions: First line for non-oncogene addicted lung cancer / Early stage NSCLC: Where do we stand in 2018?

Thursday, 12 April 2018

7:45-9:00
Immunotherapy and next-generation TKIs: From second to frontline treatment, or

8:00-8:50
Parallel sessions: Management of oligometastatic disease / Management of CT detected small nodules or

9:00-10:30
Parallel sessions: Second line in non-oncogene addiction / Young oncologist session (oligometastatic NSLCL with driver mutations + ERGR mutations trend + How to prepare a relevant clinically-based project in LC & mentorship), or

9:15-10:15
Uncommon driver alterations: Should we use off-label targeted agents?

11:00-12:30
Parallel sessions: Developments in pharmacology for systemic therapy / State of the art of PD-L1 testing / Advances in surgery / Advances in radiation

12:30-13:00
Poster lunch

14:10-14:40
Keynote lecture – Molecular and immuno landscaping in lung cancer

14:45-16:15
Relevant biomarkers for the use of immune checkpoints, or

15:00-16:00
Parallel sessions: T790M: Liquid biopsy or histological samples? / Limitations and advances of thoracic radiotherapy

16:45-18:15
Parallel sessions: How can we optimise our organisation to deliver precision oncology? / PD-L1 expression and tumor microenvironment in advanced lung cancer

Friday, 13 April 2018

8:00-8:50
Parallel sessions: Combining radiation with non-chemotherapy agents / Liquid biopsy at the initial diagnosis and during monitoring

9:00-10:30
Parallel sessions: Immunotherapy combinations / Mesothelioma: New roads through understanding biology, or

9:15-10:15
Next generation TKI: Front line or later?

11:00-12:30
Parallel sessions: Resistance to TKIs / New approaches in rare thoracic tumors / Immune checkpoint blockade: Basic mechanisms, preclinical evaluation and mechanisms of resistance

12:30-13:00
Poster lunch

14:10-14:40
Keynote lecture - Predictive biomarkers for immune checkpoints inhibitors

14:45-16:15
Parallel sessions: Guiding the best targeted treatment/ Less frequent driving alterations / Epidemiology and outcomes

16:45-18:15
Parallel sessions: ESO Lung Cancer Observatory /
How to prioritise the use of biomarkers / ESMO-IASLC best abstracts

Saturday, 14 April 2018

8:45-9:15
Keynote lecture - Early detection of lung cancer

9:20-10:50
New perspectives in the treatment of SCLC

11:20-12:50
Non-small cell neuro-endocrine tumours

 
 
 Module 1  Epidemiology, prevention, biology and pathology of lung cancer and other thoracic 
 malignancies
 
Scientific Directors: Keith Kerr and Alex Soltermann
 
 Period  Mid-April / mid-July 2018  
 ECTS  Mod 1 + 2 = 5 ECTS  
 Assessment  Test (52 multiple-choice questions)

 

 Workload
 hours
 78  
 Units   26
   - Epidemiology [Paolo Boffetta] 2
 - Risk factors and environmental exposure [TBC] 2
 - Primary prevention [Emily Stone] 2
 - Screening [John Field] 2
 - The Cancer Genome Atlas in lung cancer [Ramaswamy Govindan] 2
 - Immuno-oncology from a biological perspective: Biological principles of tumour immunology
   [Maries van den Broek]
2
 - Immuno-oncology from a biological perspective: Biomarkers from immune-oncology [Ming S. Tsao] 2
 - Molecular classification of lung cancer [Martin L. Sos] 2
 - Methods of molecular diagnostics: Tissue based [Erik Thunnissen] 2
 - Methods of molecular diagnostics: Nucleic-acid based [Nicola Normanno] 2
 - Pathological classification of lung cancer: NSCLC & SCLC [Sylvie Lantuejoul] 2
 - Epidemiology and pathological classification of rare thoracic malignancies [Andrew Nicholson] 2
 - Cancer survivorship [Dany Bell] 2
 
 Module 2  Principles of lung cancer research
 
Scientific Directors: Christian Britschgi and Solange Peters
 
 Period  Mid-July / mid-October 2018  
 ECTS  Mod 1 + 2 = 5 ECTS  
 Assessment  Test (48 multiple-choice questions)  
 Workload
 hours
 72  
 Units   24
   - Principles of basic research [Anton Berns] 2
 - Principles of translational research [Christian Britschgi] 2
 - Biobanking [TBC] 2
 - Principles of phase 1, 2, 3 clinical trials [Uriana Dafni] 2
 - Clinical trial databases and registries [Uriana Dafni] 2
 - Design and conduct of clinical trials [Anouk Neven] 2
 - Good clinical practice [Anita Hiltbrunner] 2
 - Valid end-points of clinical trials [Enriqueta Felip] 2
 - Interpretation of clinical trial results [Jean-Paul Sculier] 2
 - ESMO magnitude of clinical benefit scale [TBC] 2
 - Legal requirements and frameworks for pre-clinical and clinical reserach [Anastassia Negrouk] 2
 - Lung cancer research organisations and societies : ETOP, EORTC [Rolf Stahel] 2
  
 Seminar 2  CAS Lung Cancer programme +
 Participation in selected sessions of the ESMO Congress
 
 Date and
 place
 19-23 October 2018, Munich, Germany  
 ECTS  1  
 Assessment
 Included in final exam  
 Workload
 hours
  30
  
 Module 3
 Principles of NSCLC diagnosis and treatment
 
Scientific Directors: Isabelle Schmitt-Opitz and Suresh Senan
 
 Period
 November 2018 / mid-January 2019  
 ECTS  3  
 Assessment  Test (60 multiple-choice questions)  
 Workload
 hours
 90  
 Units

 

30
   - Clinical examination and basic lab tests 1
 - Bronchoscopy, EBUS, EUS, mediastinoscopy 1
 - Principles of standard radiologic evaluation including CT-guided biopsy and PET-CT imaging 1
 - Comorbidity assessment, comprehensive geriatric assessment 1
 - Differential diagnosis of other common thoracic malignancies 1
 - Pathology classification & TNM staging 1
 - Prognostic and predictive factors 1
 - Evaluation of treatment results: Follow-up workout, response criteria, RECIST 1
 - Principles of multidisciplinary treatment 1
 - Pre-operative risk assessment 1
 - Surgical treatment of early stage NSCLC 1
 - Stereotactic body radiotherapy for stage I NSCLC 1
 - Adjuvant chemotherapy in N positive disease 1
 - Treatment of N2 disease: Surgical treatment 1
 - Treatment of N2 disease: Neo-adjuvant systemic therapy 1
 - Treatment of N2 disease: Combined chemo-radiotherapy 1
 - Treatment of N3 disease: Systemic treatment and combined chemo-radiotherapy 1
 - Surgical treatment of T4 tumours 1
 - Multimodality treatment of sulcus superior tumours 1
 - Chemotherapy for advanced disease 2
 - Targeted therapy for advanced disease: EGFR 2
 - Targeted therapy for advanced disease: ALK 1
 - Targeted therapy for advanced disease: others 1
 - Immunotherapy for advanced disease 2

 - Combination partners for immunotherapy: chemotherapy, radiotherapy

1
 - Oligo-metastases & oligo-progression 1
 - Bone modifying agents 1
  
 Module 4

 Principles of treatment: SCLC, MPM, thymoma & thymic cancer
 
Scientific Directors: Alessandra Curioni and Martin Früh

 
 Period  Mid January / March 2019  
 ECTS
 3  
 Assessment
 Test (60 multiple-choice questions)  
 Workload
 hours
 90  
 Units

 

30
   - SCLC: Pathology, staging and prognostic factors for SCLC 1
 - SCLC: Management of very early disease with local treatment 1
 - SCLC: Multi-modality treatment of LD SCLC 2
 - SCLC: Multi-modality treatment of ED SCLC 2
 - MPM: Pathology, staging and prognostic factors 1
 - MPM: Multimodality treatment with curative intend 2
 - MPM: Systemic treatment of unresectable disease 2
 - Thymoma & thymic cancer: Pathology, staging and prognostic factors 1
 - Thymoma & thymic cancer: Surgery and multimodality concepts 2
 - Thymoma & thymic cancer: Systemic treatment 2
 - Rare thoracic cancer: Trachea 1
 - Rare thoracic cancer: Neuroendocrine tumours 2
 - Oligo-metastatic lung disease: Surgical resection 1
 - Oligo-metastatic lung disease: SBRT 1
 - Supportive therapy to systemic therapy 2
 - Palliative therapy: Dyspnoea, pleural effusion, pain 2
 - Treatment of CNS metastases 2
 - Psycho-social interventions 2
 - Guidelines ESMO, NCCN, ASCO 1
  
 Seminar 3
 CAS Lung Cancer programme, to include visits labs and clinical activities  
 Date and
 place
 April 2019, Universities of Lausanne (D1) and Zurich (D2, D3) + exam  
 ECTS  1  
 Assessment  By the chairs’ evaluation of the clinical case presentation  
 Workload
 hours
  30

 




 

Follow us